1
|
Barroeta-Espar I, Weinstock LD, Perez-Nievas BG, Meltzer AC, Siao Tick Chong M, Amaral AC, Murray ME, Moulder KL, Morris JC, Cairns NJ, Parisi JE, Lowe VJ, Petersen RC, Kofler J, Ikonomovic MD, López O, Klunk WE, Mayeux RP, Frosch MP, Wood LB, Gomez-Isla T. Distinct cytokine profiles in human brains resilient to Alzheimer's pathology. Neurobiol Dis 2018; 121:327-337. [PMID: 30336198 DOI: 10.1016/j.nbd.2018.10.009] [Citation(s) in RCA: 68] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2018] [Revised: 10/03/2018] [Accepted: 10/12/2018] [Indexed: 12/29/2022] Open
Abstract
Our group has previously studied the brains of some unique individuals who are able to tolerate robust amounts of Alzheimer's pathological lesions (amyloid plaques and neurofibrillary tangles) without experiencing dementia while alive. These rare resilient cases do not demonstrate the patterns of neuronal/synaptic loss that are normally found in the brains of typical demented Alzheimer's patients. Moreover, they exhibit decreased astrocyte and microglial activation markers GFAP and CD68, suggesting that a suppressed neuroinflammatory response may be implicated in human brain resilience to Alzheimer's pathology. In the present work, we used a multiplexed immunoassay to profile a panel of 27 cytokines in the brains of controls, typical demented Alzheimer's cases, and two groups of resilient cases, which possessed pathology consistent with either high probability (HP, Braak stage V-VI and CERAD 2-3) or intermediate probability (IP, Braak state III-IV and CERAD 1-3) of Alzheimer's disease in the absence of dementia. We used a multivariate partial least squares regression approach to study differences in cytokine expression between resilient cases and both Alzheimer's and control cases. Our analysis identified distinct profiles of cytokines in the entorhinal cortex (one of the earliest and most severely affected brain regions in Alzheimer's disease) that are up-regulated in both HP and IP resilient cases relative to Alzheimer's and control cases. These cytokines, including IL-1β, IL-6, IL-13, and IL-4 in HP resilient cases and IL-6, IL-10, and IP-10 in IP resilient cases, delineate differential inflammatory activity in brains resilient to Alzheimer's pathology compared to Alzheimer's cases. Of note, these cytokines all have been associated with pathogen clearance and/or the resolution of inflammation. Moreover, our analysis in the superior temporal sulcus (a multimodal association cortex that consistently accumulates Alzheimer's pathology at later stages of the disease along with overt symptoms of dementia) revealed increased expression of neurotrophic factors, such as PDGF-bb and basic FGF in resilient compared to AD cases. The same region also had reduced expression of chemokines associated with microglial recruitment, including MCP-1 in HP resilient cases and MIP-1α in IP resilient cases compared to AD. Altogether, our data suggest that different patterns of cytokine expression exist in the brains of resilient and Alzheimer's cases, link these differences to reduced glial activation, increased neuronal survival and preserved cognition in resilient cases, and reveal specific cytokine targets that may prove relevant to the identification of novel mechanisms of brain resiliency to Alzheimer's pathology.
Collapse
Affiliation(s)
- Isabel Barroeta-Espar
- Massachusetts General Hospital ADRC, Harvard University, 15 Parkman St #835, Boston, MA 02114, United States
| | - Laura D Weinstock
- Parker H. Petit Institute for Bioengineering & Bioscience, Georgia Institute of Technology, 315 Ferst Dr, Atlanta, GA 30332, United States; Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology, North Ave NW, Atlanta, GA 30332, United States.
| | - Beatriz G Perez-Nievas
- Massachusetts General Hospital ADRC, Harvard University, 15 Parkman St #835, Boston, MA 02114, United States
| | - Avery C Meltzer
- Massachusetts General Hospital ADRC, Harvard University, 15 Parkman St #835, Boston, MA 02114, United States
| | - Michael Siao Tick Chong
- Massachusetts General Hospital ADRC, Harvard University, 15 Parkman St #835, Boston, MA 02114, United States
| | - Ana C Amaral
- Massachusetts General Hospital ADRC, Harvard University, 15 Parkman St #835, Boston, MA 02114, United States.
| | - Melissa E Murray
- Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road South, Jacksonville, FL 32224, United States.
| | - Krista L Moulder
- Department of Neurology, Knight Alzheimer Disease Research Center, Washington University, 1 Brookings Dr, St. Louis, MO 63130, United States.
| | - John C Morris
- Department of Neurology, Knight Alzheimer Disease Research Center, Washington University, 1 Brookings Dr, St. Louis, MO 63130, United States.
| | - Nigel J Cairns
- Department of Neurology, Knight Alzheimer Disease Research Center, Washington University, 1 Brookings Dr, St. Louis, MO 63130, United States.
| | - Joseph E Parisi
- Department of Neurology, Mayo Clinic, 200 1st St SW, Rochester, MN 55905, United States.
| | - Val J Lowe
- Department of Radiology, Mayo Clinic, 200 1st St SW, Rochester, MN 55905, United States.
| | - Ronald C Petersen
- Department of Neurology, Mayo Clinic, 200 1st St SW, Rochester, MN 55905, United States.
| | - Julia Kofler
- Department of Pathology, University of Pittsburgh School of Medicine, 4200 Fifth Ave, Pittsburgh, PA 15260, United States.
| | - Milos D Ikonomovic
- Department of Neurology, University of Pittsburgh School of Medicine, 4200 Fifth Ave, Pittsburgh, PA 15260, United States; Department of Psychiatry, University of Pittsburgh School of Medicine, 3811 DeSoto Street, Pittsburgh, PA 15260, United States.
| | - Oscar López
- Department of Neurology, University of Pittsburgh School of Medicine, 4200 Fifth Ave, Pittsburgh, PA 15260, United States.
| | - William E Klunk
- Department of Psychiatry, University of Pittsburgh School of Medicine, 3811 DeSoto Street, Pittsburgh, PA 15260, United States
| | - Richard P Mayeux
- The Taub Institute for Research on Alzheimer's Disease and the Aging Brain and The Gertrude H. Sergievsky Center, Columbia University, 116th St & Broadway, New York, NY 10027, United States.
| | - Matthew P Frosch
- Massachusetts General Hospital ADRC, Harvard University, 15 Parkman St #835, Boston, MA 02114, United States.
| | - Levi B Wood
- Parker H. Petit Institute for Bioengineering & Bioscience, Georgia Institute of Technology, 315 Ferst Dr, Atlanta, GA 30332, United States; Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology, North Ave NW, Atlanta, GA 30332, United States; Georgia W. Woodruff School of Mechanical Engineering, Georgia Institute of Technology, 315 Ferst Dr, Atlanta, GA 30332, United States; Beth Israel Deaconess Cancer Center, 330 Brookline Ave, Boston, MA 02215, United States.
| | - Teresa Gomez-Isla
- Massachusetts General Hospital ADRC, Harvard University, 15 Parkman St #835, Boston, MA 02114, United States.
| |
Collapse
|
2
|
Marquié M, Verwer EE, Meltzer AC, Kim SJW, Agüero C, Gonzalez J, Makaretz SJ, Siao Tick Chong M, Ramanan P, Amaral AC, Normandin MD, Vanderburg CR, Gomperts SN, Johnson KA, Frosch MP, Gómez-Isla T. Lessons learned about [F-18]-AV-1451 off-target binding from an autopsy-confirmed Parkinson's case. Acta Neuropathol Commun 2017; 5:75. [PMID: 29047416 PMCID: PMC5648451 DOI: 10.1186/s40478-017-0482-0] [Citation(s) in RCA: 77] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2017] [Accepted: 10/11/2017] [Indexed: 02/07/2023] Open
Abstract
[F-18]-AV-1451 is a novel positron emission tomography (PET) tracer with high affinity to neurofibrillary tau pathology in Alzheimer’s disease (AD). PET studies have shown increased tracer retention in patients clinically diagnosed with dementia of AD type and mild cognitive impairment in regions that are known to contain tau lesions. In vivo uptake has also consistently been observed in midbrain, basal ganglia and choroid plexus in elderly individuals regardless of their clinical diagnosis, including clinically normal whose brains are not expected to harbor tau pathology in those areas. We and others have shown that [F-18]-AV-1451 exhibits off-target binding to neuromelanin, melanin and blood products on postmortem material; and this is important for the correct interpretation of PET images. In the present study, we further investigated [F-18]-AV-1451 off-target binding in the first autopsy-confirmed Parkinson’s disease (PD) subject who underwent antemortem PET imaging. The PET scan showed elevated [F-18]-AV-1451 retention predominantly in inferior temporal cortex, basal ganglia, midbrain and choroid plexus. Neuropathologic examination confirmed the PD diagnosis. Phosphor screen and high resolution autoradiography failed to show detectable [F-18]-AV-1451 binding in multiple brain regions examined with the exception of neuromelanin-containing neurons in the substantia nigra, leptomeningeal melanocytes adjacent to ventricles and midbrain, and microhemorrhages in the occipital cortex (all reflecting off-target binding), in addition to incidental age-related neurofibrillary tangles in the entorhinal cortex. Additional legacy postmortem brain samples containing basal ganglia, choroid plexus, and parenchymal hemorrhages from 20 subjects with various neuropathologic diagnoses were also included in the autoradiography experiments to better understand what [F-18]-AV-1451 in vivo positivity in those regions means. No detectable [F-18]-AV-1451 autoradiographic binding was present in the basal ganglia of the PD case or any of the other subjects. Off-target binding in postmortem choroid plexus samples was only observed in subjects harboring leptomeningeal melanocytes within the choroidal stroma. Off-target binding to parenchymal hemorrhages was noticed in postmortem material from subjects with cerebral amyloid angiopathy. The imaging-postmortem correlation analysis in this PD case reinforces the notion that [F-18]-AV-1451 has strong affinity for neurofibrillary tau pathology but also exhibits off-target binding to neuromelanin, melanin and blood components. The robust off-target in vivo retention in basal ganglia and choroid plexus, in the absence of tau deposits, meningeal melanocytes or any other identifiable binding substrate by autoradiography in the PD case reported here, also suggests that the PET signal in those regions may be influenced, at least in part, by biological or technical factors that occur in vivo and are not captured by autoradiography.
Collapse
|
3
|
Marquié M, Normandin MD, Meltzer AC, Chong MST, Andrea NV, Antón-Fernández A, Klunk WE, Mathis CA, Ikonomovic MD, Debnath M, Bien EA, Vanderburg CR, Costantino I, Makaretz S, DeVos SL, Oakley DH, Gomperts SN, Growdon JH, Domoto-Reilly K, Lucente D, Dickerson BC, Frosch MP, Hyman BT, Johnson KA, Gómez-Isla T. Pathological correlations of [F-18]-AV-1451 imaging in non-alzheimer tauopathies. Ann Neurol 2017; 81:117-128. [PMID: 27997036 PMCID: PMC5319193 DOI: 10.1002/ana.24844] [Citation(s) in RCA: 157] [Impact Index Per Article: 22.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2016] [Revised: 11/08/2016] [Accepted: 12/04/2016] [Indexed: 12/13/2022]
Abstract
OBJECTIVE Recent studies have shown that positron emission tomography (PET) tracer AV-1451 exhibits high binding affinity for paired helical filament (PHF)-tau pathology in Alzheimer's brains. However, the ability of this ligand to bind to tau lesions in other tauopathies remains controversial. Our goal was to examine the correlation of in vivo and postmortem AV-1451 binding patterns in three autopsy-confirmed non-Alzheimer tauopathy cases. METHODS We quantified in vivo retention of [F-18]-AV-1451 and performed autoradiography, [H-3]-AV-1451 binding assays, and quantitative tau measurements in postmortem brain samples from two progressive supranuclear palsy (PSP) cases and a MAPT P301L mutation carrier. They all underwent [F-18]-AV-1451 PET imaging before death. RESULTS The three subjects exhibited [F-18]-AV-1451 in vivo retention predominantly in basal ganglia and midbrain. Neuropathological examination confirmed the PSP diagnosis in the first two subjects; the MAPT P301L mutation carrier had an atypical tauopathy characterized by grain-like tau-containing neurites in gray and white matter with heaviest burden in basal ganglia. In all three cases, autoradiography failed to show detectable [F-18]-AV-1451 binding in multiple brain regions examined, with the exception of entorhinal cortex (reflecting incidental age-related neurofibrillary tangles) and neuromelanin-containing neurons in the substantia nigra (off-target binding). The lack of a consistent significant correlation between in vivo [F-18]-AV-1541 retention and postmortem in vitro binding and tau measures in these cases suggests that this ligand has low affinity for tau lesions primarily made of straight tau filaments. INTERPRETATION AV-1451 may have limited utility for in vivo selective and reliable detection of tau aggregates in these non-Alzheimer tauopathies. ANN NEUROL 2017;81:117-128.
Collapse
Affiliation(s)
- Marta Marquié
- MassGeneral Institute for NeuroDegenerative Disease, Charlestown, MA
- Department of Neurology, Massachusetts General Hospital, Boston, MA
| | | | - Avery C. Meltzer
- MassGeneral Institute for NeuroDegenerative Disease, Charlestown, MA
- Department of Neurology, Massachusetts General Hospital, Boston, MA
| | - Michael Siao Tick Chong
- MassGeneral Institute for NeuroDegenerative Disease, Charlestown, MA
- Department of Neurology, Massachusetts General Hospital, Boston, MA
| | | | | | - William E. Klunk
- Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA
| | - Chester A. Mathis
- Department of Radiology, University of Pittsburgh School of Medicine, Pittsburgh, PA
| | - Milos D. Ikonomovic
- Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, PA
- Geriatric Research Education and Clinical Center, VA Pittsburgh Clinical System, Pittsburgh, PA
| | - Manik Debnath
- Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA
| | - Elizabeth A. Bien
- MassGeneral Institute for NeuroDegenerative Disease, Charlestown, MA
- Department of Neurology, Massachusetts General Hospital, Boston, MA
- Harvard Neurodiscovery Center, Massachusetts General Hospital, Boston, MA
| | - Charles R. Vanderburg
- MassGeneral Institute for NeuroDegenerative Disease, Charlestown, MA
- Department of Neurology, Massachusetts General Hospital, Boston, MA
- Harvard Neurodiscovery Center, Massachusetts General Hospital, Boston, MA
| | - Isabel Costantino
- MassGeneral Institute for NeuroDegenerative Disease, Charlestown, MA
| | - Sara Makaretz
- Department of Neurology, Massachusetts General Hospital, Boston, MA
| | - Sarah L. DeVos
- MassGeneral Institute for NeuroDegenerative Disease, Charlestown, MA
- Department of Neurology, Massachusetts General Hospital, Boston, MA
| | - Derek H. Oakley
- MassGeneral Institute for NeuroDegenerative Disease, Charlestown, MA
- C.S. Kubik Neuropathology Center, Massachusetts General Hospital, Boston, MA
| | - Stephen N. Gomperts
- MassGeneral Institute for NeuroDegenerative Disease, Charlestown, MA
- Department of Neurology, Massachusetts General Hospital, Boston, MA
| | - John H. Growdon
- Department of Neurology, Massachusetts General Hospital, Boston, MA
| | | | - Diane Lucente
- Center for Human Genetic Research, Massachusetts General Hospital, Boston, MA
| | | | - Matthew P. Frosch
- MassGeneral Institute for NeuroDegenerative Disease, Charlestown, MA
- C.S. Kubik Neuropathology Center, Massachusetts General Hospital, Boston, MA
| | - Bradley T. Hyman
- MassGeneral Institute for NeuroDegenerative Disease, Charlestown, MA
- Department of Neurology, Massachusetts General Hospital, Boston, MA
| | - Keith A. Johnson
- Department of Neurology, Massachusetts General Hospital, Boston, MA
| | - Teresa Gómez-Isla
- MassGeneral Institute for NeuroDegenerative Disease, Charlestown, MA
- Department of Neurology, Massachusetts General Hospital, Boston, MA
| |
Collapse
|